ClinicalTrials.gg
RecruitingNCT05339789Updated Feb 16, 2024

Long-term Surgical Treatment Outcome of Peri-implantitis Lesions

An observational study in Peri-Implantitis, sponsored by Malmö University. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by Malmö University · Observational

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
650
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Peri-Implantitis with a site in Sweden — 5 open to participants now, 6 under way, none of them phase 3. Peri-Implantitis · Sweden.

Started
2020
with 1 other
Observational
9 of 21
3 open now
Registered
15th of 21
by date
Lead sponsor
3 of 21
Malmö University

Among the 21 studies in Peri-Implantitis with a site in Sweden, this one is one of 2 that started in 2020, is one of 9 observational ones, and was the 15th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

5 of the 21 studies in Peri-Implantitis with a site in Sweden are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Peri-Implantitis with a site in Sweden, or all of them as a file.
02

Study summary

The surgical treatment outcome of patients that have been or are consecutively treated at the University of Malmö, at Blekinge hospital, and at the Dental Clinic of the Sigmund Freud University Vienna will be evaluated on an a regular base; specifically all patients treated since 2014 and those receiving treatment in the future, will be regularly assessed, max. once per year after the 1-year control from the surgical intervention for clinical and radiographic assessment of healing. Clinical peri-implant parameters (e.g., probing pocket depth) and peri-implant sulcus fluid (PISF) are collected, and a peri-apical radiographic examination is made. Further, from 200 patients treated in the future, the inflammatory peri-implant lesion will be collected and subjected to histological, microbiological, and molecular analysis. The removal of these lesions is a standard procedure and performed in all patients independent of study participation; i.e., the lesion has anyway to be removed during surgery and if the lesions are not stored, they would be thrown.

03

Conditions studied

  • Peri-Implantitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients being treated since 2014 and continuously being treated will be called in for regular check-ups after the surgical intervention and an examination for study purpose will be performed annually.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients being treated since 2014 and continuously being treated will be called in for regular check-ups after the surgical intervention and an examination for study purpose will be performed annually.

Exclusion criteria

Exclusion criteria:

  • implant loss
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
650 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 12 months postoperative

  2. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 24 months postoperative

  3. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 36 months postoperative

  4. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 48 months postoperative

  5. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 60 months postoperative

  6. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 72 months postoperative

  7. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 84 months postoperative

  8. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 96 months postoperative

  9. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 108 months postoperative

  10. Disease resolution (Binary: yes/no)

    Disease resolution will be defined as peri-implant probing pocket depth ≤ 5 mm and no excessive bleeding and/or suppuration on probing.

    Time frame: 120 months postoperative

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2030, 124 months after the start.

Of 33 non-industry observational studies under Peri-Implantitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 77. This study's planned 124 months is above that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 8 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2022
First posted
Apr 21, 2022
StartActual
Aug 30, 2020
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Feb 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05339789
Lead sponsor
Malmö University
Collaborators
Medical University of Vienna, Sigmund Freud PrivatUniversitat, Blekinge County Council Hospital
Responsible party
Kristina Bertl (Principal Investigator, Malmö University) — Principal investigator
First posted
Apr 21, 2022
Start date
Aug 30, 2020
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Feb 16, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion